^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1545p - DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
Published date:
09/14/2020
Excerpt:
The subgroup of pts with PC tumors harboring somatic DDR gene mut, particularly functional BRCA1, BRCA2 or PALB2, have higher response rate and longer PFS with oxaplatin-based chemotherapy.
